El consorcio presenta varios socios o asociados que han demostrado interés en el presente proyecto y que actuarán como observadores/asesores. Estos asociados provienen del mundo académico, instituciones sanitarias y de la industria. El consorcio, si fuese requerido a ello, puede presentar documentación incluidos los CV de estos socios demostrando su interés en el proyecto. Todos ellos son personas de reconocido prestigio y expertos en el campo de la resistencia a insulina/Diabetes y cuya opinión sobre las actividades del consorcio y sugerencias deberán ser tenidas en cuenta. Aunque parte de los observadores ya conocen bien el consorcio por haber ejercido esta función en la pasada convocatoria, al haber nuevas incorporaciones y como se indica más adelante, los observadores tendrán un primer contacto con el consorcio en el contexto del nuevo proyecto en lo que denominamos simposio cero. Este simposio tendrá como objetivo establecer el punto de partida y la dirección de progreso del proyecto. Los observadores, como en el consorcio MOIR de la convocatoria precedente asistirán a los simposios anuales para poder seguir la evolución y el progreso de las actividades así como para verter sus opiniones al respecto.

Dr. Fernando Corrales is the head of the Functional Proteomics Unit at the CNB. This laboratory will provide resources for identifying, characterizing, and quantifying proteins, whether purified or as complex mixtures from any sample from the different groups of the MOIR-ACTOME consortium. The laboratory will perform unsupervised protein quantification using label-free or isobaric labeling, targeted quantification, analysis of HLA peptide repertoires, analysis of post-translational modifications, and structural proteomics. In the period 2019-2020, this laboratory has conducted 4138 proteomic analyses for 404 users, which included sample preparation, nLCMS/MS analysis, and data processing with preliminary functional interpretation, thus endorsing its extensive experience in the field of proteomics and will be of great help in achieving the objectives of the MOIR-ACTOME consortium.

Vice President R&D
Head Cardiovascular/Metabolic Diseases
Center of Excellence
One MedInmmune Way
Gaithersburg, MD 20878, USA

Dr. Cristina Rondinone is the Director of the Metabolic Diseases section at Medimmune LLC (Gaithersburg, MD, USA). After a long career in academia, Dr. Cristina Rondinone moved into the industry where she has continued to be interested in research and the search for new therapeutic targets, particularly in the field of insulin resistance and diabetes. Hence her interest in this consortium. Additionally, Dr. Rondinone has collaborated with some members of this consortium such as Dr. A. M. Valverde from the Alberto Sols Biomedical Research Institute of CSIC.

El profesor Andrew Schally es Catedrático del la Facultad de Medicina de la Universidad de Miami, Florida, US. Obtuvo el premio Nobel de medicina en 1977. El profesor Schally fue uno de los primeros investigadores que describieron la existencia de determinados agentes humorales que interactúan entre la hipófisis y el hipotálamo. Hoy en día el papel del hipotálamo en la homeostasis calórica y probablemente en el desarrollo de la resistencia insulina parece indiscutible y el apoyo y observación enriquece enormemente el presente proyecto.

El profesor  Manuel Serrano Ríos es Catedrático de la Facultad de Medicina de la Universidad Complutense de Madrid y del Hospital Clínico de San Carlos donde ha venido ejerciendo su labor docente y asistencial. El Profesor Serrano Rios es una de las referencias de la Diabetes en España. Su reconocimiento internacional le ha llevado a recibir diversos premios. Es editor y referee de diversas revistas, pertenece a la Fundación Lilly. No solo ha sido pionero sino un líder avanzado e indiscutible en el campo de la diabetes en España y que ha combinado la labor asistencial con la investigación de forma ejemplar.

Publicaciones:
250 publicaciones originales en revistas nacionales e internacionales. De ellos 169 indexed (PubMed.), 89% Contribuciones originales. Primer autor o senior (último) correspondiente: 75%.
Bibliometria (informe CINDOC) 2010
2.498 Citas (total)
Factor de Impacto Acumulado (Total): 587.246
70 capítulos de Libros.
Editor de 10  Libros (6 en Español, 4 en Inglés).
350 comunicaciones científicas a reuniones (Congresos) nacionales e internacionales.
Chairman invitado en 250 Sesiones científicas en Conferencias Nacionales e Internacionales.
Profesor Visitante en la Universidad de Ohio State, US; Cayetano Heredia, Lima, Perú; Universidad Católica de Chile, y en varias otras de Sudamérica.

Trayectoria Académica 
Doctor en Medicina. Sobresaliente “Cum Laude”, Universidad Complutense, 1971.
Profesor Adjunto (oposición Cuerpo Nacional) Patología/Clínica Médica. Universidad Sutónoma, Madrid, 1975-76.
Profesor Agregado Patología/Clínica Médica (oposición). Universidad Autónoma Barcelona 1976-78.
Profesor Agregado Patología Genera (traslado). Universidad Complutense adrid 1978-80.
Catedrático de Patología General (acceso). Universidad de Oviedo, 1981-86.
Catedrático de Medicina Interna (oposición). Universidad Complutense Madrid, 1986-2005.
Profesor Emérito de la Universidad Complutense de Madrid, Facultad de Medicina 2005-2008 .

Actividades Profesionales
Tesinas de Licenciatura: 15. Tesis Doctorales: 24.
Seminarios “Workshops”, Cursos, Mesas Redondas: 250 España; 120 Latino-America; 80, Europa/otros países.
Conferenciante invitado (Sesiones Plenarias, Congresos): 150 España; 50 Latino-América; 20 Europa/otros países.

Actividades Organización
Presidente XII Congreso International Diabetes Federation (IDF), Madrid 1985.
Presidente II International Symposium on Insulin Receptor. Madrid 1986.
Presidente IV Mediterranean Congress in Diabetes. Madrid 1992.
Presidente I Congreso Mundial de Nutrición y Lacteos. Madrid 1993.
Presidente I Congreso Nacional de <nutrición Básica y Aplicada (SENBA). Madrid, 1996.
Académico de Número de la Real Academia de Medicina. Madrid (2009) 

Premios
Medalla de Oro Hagedorn. Investigación Diabetológica 1973.
Medalla y Premio “Instituto Diabetes” Universidad Zagreb. Lección Conmemorativa VukVrhovac”, 1983.
Premio Sociedad Española de Diabetes Investigación Clínica, 1990.
Medalla Oro, Conferenciante XXX Lección Conmemorativa “Jiménez Díaz”, 1998.
Medalla de Oro de la Sociedad Mediterránea para el estudio de la Diabetes. Marrakesh, 2000.
Lección Conmemorativa Dr. Ricardo Fuster, Fundación Valenciana de Estudios Avanzados. Valencia (España), 2000.
Medalla de Oro de la Sociedad Española de Nutrición Básica y Aplicada (SENBA). Palma de Mallorca (España), 2001.
Premio Nacional de Investigación de la Fundación Científica “Caja Rural de Zamora”. Zamora (España), 2003.
Medalla de oro a la Trayectoria Científica de la Sociedad Española de Diabetes. Madrid (España), 2006.
Premio de la Sociedad Española de Obesidad a la Trayectoria Profesional. Zaragoza, Octubre 2007.
Premio a la  Comunicación enla Convocatoria del Siglo XIII
Premio Científico Hospital Clínico San Carlos: “Effect of ENPP1 (PC-1)K121 Q Polymorphism on type 2 Diabetes”. Madrid, España, 8 Noviembre 2007.
Distinguished Scientific Career Award, Lilly FundationAward 2008.

He is Professor of Metabolism and Molecular Nutrition at the University of Cambridge (United Kingdom) and has made fundamental contributions in the field of insulin resistance and obesity that have helped to understand the molecular basis of Metabolic Syndrome. Particularly, he is known for proposing that pharmacological activation of brown adipose tissue can be used to treat overweight and obesity. Similarly, Prof. VidalPuig has been recognized worldwide for proposing that excessive expansion of adipose tissue is an important factor in the pathogenesis of insulin resistance in the context of positive energy balance. His academic commitments outside the UK include his affiliation with the Centre for Human Gender Artificial Intelligence at the Business School of the National University of Singapore. Since 2019, he has been associated with the newly opened Cambridge-Nanjing University Centre for Technology. As a Visiting Professor at Nanjing University, he participates in the study of the obesity and diabetes epidemic occurring in China. He is also Chair of the Life Science Panel and has been awarded the Principal Investigator Prize by the European Research Council. Prof. VidalPuig combines clinical practice with basic research and has been a fundamental support in the development of the previous MOIR1 and MOIR2 projects, as well as in MOIR-ACTOME. His participation in previous editions of the consortium has been key in advising the consortium on the execution of the program at the scientific level, as well as in management, and he has participated in some joint publications with the LIPOBETA group.

La investigación y desarrollo de nuevos fármacos es una tarea larga y complicada. El entorno sanitario global presenta desafíos sin precedentes que obligan a adoptar nuevos procedimientos de trabajo. Por ello, Lilly evoluciona de manera constante para poder responder de manera eficaz a los retos que surgen en el sector farmacéutico. En todo momento se plantean preguntas, cada vez más difíciles, para obtener respuestas, cada vez mejores.

La misión de Lilly es la de crear y suministrar fármacos innovadores que permitan gozar de una vida más larga, más sana y más activa, en base a una serie de valores como la ética, la transparencia y la excelencia.

Por parte de la empresa LIlly, participan como observadores externos en el consorcio MOIR:
Dr. José Antonio Sacristán del Castillo
Director Médico, Lilly, S.A.

Dr. Jesús Reviriego
Medical Fellow. Lead CRP

Dr. Luis Alberto Vazquez

She obtained her PhD in Biochemistry (2008) from the Complutense University (Madrid, Spain). As a postdoctoral fellow (2008-2014), she joined the Spanish National Research Council (CSIC) (Madrid, Spain) and focused on studying the molecular mechanisms involved in peripheral insulin action, especially the molecular mechanisms of hepatic insulin resistance and sensitivity. In (2013-2014), she moved to the University of Cambridge (Cambridge, United Kingdom). Since 2015, she has been an independent researcher at the Institute of Health Research "University Hospital La Princesa", leading a laboratory based on the study of molecular mechanisms involved in the progression of chronic liver diseases and their metabolic implications.
Dr. Águeda González Rodríguez conducts high-level translational research focused on the study of metabolic syndrome and liver diseases. Her main research line is based on the identification and characterization of new molecular targets involved in the pathogenesis of non-alcoholic fatty liver disease (NAFLD), with special emphasis on studying the mechanisms responsible for the progression of liver disease from the initial stage of simple steatosis to the development of steatohepatitis and fibrosis.

Dr. Alba Galdón, graduated in Medicine and Surgery from the Complutense University of Madrid and specializing in Endocrinology and Nutrition since 2014, is an attending physician in the Endocrinology and Nutrition Department at the Gregorio Marañón University General Hospital (GMUGH) and responsible for the Comprehensive Management of Type 2 Diabetes Mellitus clinic. She is also a member of the Research Unit of the Endocrinology Department at GMUGH and currently involved in more than 20 projects in the field of diabetes mellitus, metabolic syndrome, cardiovascular risk, and neuroendocrinology. Additionally, she is the author of national and international publications in this area. She is also a Teaching Collaborator at the Faculty of Medicine of the Autonomous University of Madrid (2015-2019), Clinical Teaching Collaborator at the Faculty of Medicine of the Francisco de Vitoria University of Madrid (2016-2019), mentor of students in External Curricular Internships at the Catholic University of Murcia (2018-2019), and currently a collaborator in Practical Teaching at the Department of Medicine of the Complutense University of Madrid since 2020. Dr. Galdón collaborates with the LIPOBETA group in the study of obese patients without diabetes with renal damage (WP3). She will perform the clinical follow-up of these patients in the hospital and participate in the consortium's activities.

Professor Jose Luis Bartha Rasero, graduated and PhD in Medicine and Surgery, is currently Professor of Obstetrics and Gynecology and Delegate of the Dean of the Faculty of Medicine of UAM for La Paz University Hospital and Head of the Obstetrics and Gynecology Department and the Fetal Medicine Unit at this hospital where he carries out important clinical, research, and teaching work. He also directs several research projects in the Ultrasound and Maternal Fetal Medicine Unit at Clínica Santa Elena in Madrid. Previously, he worked as a lecturer at the University of Cadiz and at the University of Bristol in the United Kingdom where he held the position of Senior Lecturer linked to the Fetal Medicine Unit of St Michael's Hospital as a Consultant for several years. His main areas of research are Diabetes and Obesity during Pregnancy, Inflammation during Pregnancy, and Fetal Medicine. His research activity has resulted in the publication of more than 120 articles, more than half of them in journals with great international impact. He has also published book chapters and frequently participates as a speaker at national and international congresses, being a person of recognized prestige within his professional field. Among other roles, he is an active member of the European Association for the Study of Diabetes, the Spanish Diabetes Society (SED) in the Diabetes and Pregnancy group, and the Spanish Society of Gynecology and Obstetrics (SEGO) in the Perinatal Medicine section. He is currently the coordinator of the Spanish Group of Diabetes during Pregnancy (GEDE).

Dr. Enrique Morales, Hospital 12 de Octubre, Madrid, is a specialist practicing his profession at the highest level in a University Hospital. In this regard, he has carried out his healthcare activity since 1995, first as a resident and later as an attending physician in different areas of the department (Clinical Nephrology, Dialysis, and Renal Transplantation). Dr. Morales is professionally dedicated to teaching, an education professional who necessarily shares with other professionals from other specialties basic functions aimed at teaching others. Regarding this point, it is important to highlight his role as a tutor from 2005 to 2013 and vice president of the Teaching Committee of Hospital 12 de Octubre. He is a professional with scientific and research interests, conducting studies in different areas of the specialty (Clinical Nephrology: glomerular pathology, chronic proteinuric nephropathies, obesity and kidney, malignant arterial hypertension, etc.; Hemodialysis: parenteral nutrition, immune system and dialysis, vascular access, vascular calcifications, etc.; and Renal Transplantation: donation after circulatory death, early renal transplantation, transplantation in elderly patients, etc.). This activity has resulted in different publications, grant applications, and funding for clinical studies to continue with this important activity.

The research team "Nuclear Receptor Signaling" led by Dra. Mercedes Ricote was established as a research group at the National Center for Cardiovascular Research (CNIC) in 2004. Recently, their laboratory has been relocated to the National Center for Biotechnology (CNB-CSIC), where she is a researcher at the CSIC. The research team of Dra. Mercedes Ricote is composed of members with extensive experience in the study of macrophages and nuclear receptors in the context of chronic inflammatory diseases such as diabetes and atherosclerosis. The principal investigator has been working for over 20 years in the field of nuclear receptor signaling in metabolic and cardiovascular diseases, and has obtained funding from public sources (SAF2017-90604-REDT, RTI2018-095928-B-I00, PID2021-12255OB-B-I00), regional (B2017/BMD-3684, P2022/BMD-7227), private (Mutua Madrileña Foundation, La Marató TV3), and European (FP7-PEOPLE-2005-IRG, FP7-PEOPLE-2008-IEF, FP7-PEOPLE-2009-RG, EFSD/Lilly Research Fellowships, FP7-PEOPLE-2013-ITN) for conducting studies focused on elucidating the molecular mechanisms that regulate the activation and differentiation of macrophages in homeostasis and in metabolic and cardiovascular diseases. Additionally, she has recently initiated a new line of research examining signal transmission between mothers and neonates, and its impact on energy homeostasis control. To carry out these projects, the research group has established a wide range of cutting-edge technologies such as omics (RNAseq, ChIPseq, and ATACseq), animal models, conditional knockout mice, and advanced non-invasive imaging techniques.

Furthermore, Dra. Mercedes Ricote has supervised 7 doctoral theses and has overseen numerous master's theses and internships of vocational training students. Dra. Mercedes Ricote is invited to national and international congresses as a speaker and moderator at the level of "Keystone Symposium", "EMBO", FEBS..., which indicates that she is a researcher of recognized prestige in the field of nuclear receptors. The research group has international collaborations with Drs. C. Glass (UCSD, La Jolla, USA), J. Cancelas (Cincinnati Children's Hospital, USA), D. Metzger (IGBMC, France), E. Treuter (Karolinksa Institute, Stockholm, Sweden); as well as national collaborations with groups belonging to MOIR2: Drs. G. Medina (URJC, Madrid) and M.P. Ramos (CEU, Madrid).

Funding for the last 5 years:

• [2023-2026]. COMMUNITY OF MADRID. Advancing in the understanding of new markers, mechanisms, and tissue interactome in situations of insulin resistance. (P2022/BMD-7227). PI: Dr. M. Ricote.


• [2022-2025]. MINISTRY OF SCIENCE, INNOVATION AND UNIVERSITIES. Transcriptional and epigenetic control of the development of tissue-resident macrophages by nuclear receptors: role of the niche. (PID2021-12255OB-B-I00). PI: Dr. M. Ricote.


• [2019-2021]. MINISTRY OF SCIENCE, INNOVATION AND UNIVERSITIES. Role of the nuclear receptor RXR in the origin, differentiation, and functions of tissue macrophages. (RTI2018-095928-B-100). PI: Dr. M. Ricote.


• [2018-2020]. MINISTRY OF ECONOMY AND COMPETITIVENESS Thematic network of nuclear receptors in cancer, metabolism, and inflammation. (SAF2017-90604-REDT). IP: Dr. M. Ricote. Coordinator: Dr. M. Ricote.


• [2018-2021]. COMMUNITY OF MADRID. Molecular Mechanisms and Intertissue Communication in Insulin Resistance. (B2017/BMD-3684). IP: Dr. M. Ricote. Coordinator: Dr. G. Medina.


• [2017-2019]. TV3 MARATÓ FOUNDATION. Systemic and tissue-specific control by nuclear receptors of obesity-induced insulin resistance. (ref. 201605-32). IP: Dr. M. Ricote. Coordinator: Dr. C. Caelles Franch.

MEMBERS

Team

•	Dra. Mercedes Ricote Pacheco	ORCID: 0000-0002-8090-8902
•	Jorge Mínguez Martínez	ORCID: 0000-0002-2980-6142
•	Laura Martín Aguado	ORCID: 0000-0002-1917-9077
•	Laura Casablanca

LINKS

• CNB - Nuclear Receptor Signaling - Dr. Mercedes Ricote


• CNIC - Nuclear Receptor Signaling Laboratory


• Nurcamein - Spanish Network of Nuclear Receptor Research

PUBLICATIONS OF THE LAST 5 YEARS

Scientific Publications

2023

Paredes A, Justo-Méndez R, Jiménez-Blasco D, et al. γ-Linolenic acid in maternal milk drives cardiac metabolic maturation. Nature. 2023 ;618(7964):365-73. doi: 10.1038/s41586-023-06068-7

Menéndez-Gutiérrez MP, Porcuna J, Nayak R, et al. Retinoid X receptor promotes hematopoietic stem cell fitness and quiescence and preserves hematopoietic homeostasis. Blood .2023 ;141(6):592-608. doi: 10.1182/blood.2022016832

2022

Di Martino O, Ferris MA, Hadwiger G, et al. RXRA DT448/9PP generates a dominant active variant capable of inducing maturation in acute myeloid leukemia cells. Haematol . 2022 ;107(2):417-26. doi: 10.3324/haematol.2021.278603

2021

Porcuna J, Mínguez-Martínez J, Ricote M. The PPARα and PPARγ Epigenetic Landscape in Cancer and Immune and Metabolic Disorders. IJMS . 2021 ;22(19):10573. doi: 10.3390/ijms221910573

Paredes A, Santos-Clemente R, Ricote M. Untangling the Cooperative Role of Nuclear Receptors in Cardiovascular Physiology and Disease. IJMS . 2021 ;22(15):7775. doi:10.3390/ijms22157775

Font-Díaz J, Jiménez-Panizo A, Caelles C, et al. Nuclear receptors: Lipid and hormone sensors with essential roles in the control of cancer development. Seminars in Cancer Biology. 2021; 73:58-75. doi: 10.1016/j.semcancer.2020.12.007

Blanco-Domínguez R, Sánchez-Díaz R, De La Fuente H, et al. A Novel Circulating Noncoding Small RNA for the Detection of Acute Myocarditis. N Engl J Med . 2021 ;384(21):2014-27. doi: 10.1056/NEJMoa2003608

Di Martino O, Niu H, Hadwiger G, et al. Endogenous and combination retinoids are active in myelomonocytic leukemias. Haematol .2021 ; doi: 10.3324/haematol.2020.264432

2020

Muro-Pastor MI, Cutillas-Farray Á, Pérez-Rodríguez L, et al. CfrA, a Novel Carbon Flow Regulator, Adapts Carbon Metabolism to Nitrogen Deficiency in Cyanobacteria. Plant Physiol . 2020 ;184(4):1792-810. doi: 10.1104/pp.20.00802

Casanova-Acebes M, Menéndez-Gutiérrez MP, Porcuna J,et al. RXRs control serous macrophage neonatal expansion and identity and contribute to ovarian cancer progression. Nat Commun . 2020 ;11(1):1655. doi: 10.1038/s41467-020-15371-0

Alonso-Herranz L, Sahún-Español Á, Paredes A, et al. Macrophages promote endothelial-to-mesenchymal transition via MT1-MMP/TGFβ1 after myocardial infarction. eLife . 2020 ;9:e57920. doi: 10.7554/eLife.57920

Porcuna J, Menéndez-Gutiérrez MP, Ricote M. Molecular control of tissue-resident macrophage identity by nuclear receptors. Current Opinion in Pharmacology . 2020 ;53:27-34. doi: 10.1016/j.coph.2020.04.001

Ting SM, Zhao X, Sun G, et al. Brain Cleanup as a Potential Target for Poststroke Recovery: The Role of RXR (Retinoic X Receptor) in Phagocytes. Stroke . 2020 ;51(3):958-66. doi: 10.1161/STROKEAHA.119.02731

2019

Alonso-Herranz L, Porcuna J, Ricote M. Isolation and Purification of Tissue Resident Macrophages for the Analysis of Nuclear Receptor Activity. En: Gage MC, Pineda-Torra I, editores. Lipid-Activated Nuclear Receptors . New York, NY: Springer New York; 2019 . p. 59-73. Disponible en: http://link.springer.com/10.1007/978-1-4939-9130-3_5

Binek A, Rojo D, Godzien J, et al. Flow Cytometry Has a Significant Impact on the Cellular Metabolome. J Proteome Res. Jan 4;18(1):169-181, 2019. Disponible en: https://pubs.acs.org/doi/epdf/10.1021/acs.jproteome.8b00472

Professor Jesús Argente Oliver is a professor of Pediatrics at UAM and Head of the Pediatrics and Endocrinology Department at the University Children's Hospital Niño Jesús. He completed his pre-doctoral studies at the Hospital for Sick Children (Toronto, Canada) and Rene Descartes University (Paris, France). He received postdoctoral training at the Universities of Paris (René Descartes), Virginia (Charlottesville, VA, USA) as a Fulbright and Washington (Seattle, WA, USA). He was president of the European Society for Pediatric Endocrinology ESPE (2002) and the Spanish Society of Pediatric Endocrinology (2004-2008). He is a corresponding academic of the Royal Academy of National Medicine of Madrid and the Royal Academy of Medicine of Zaragoza. He has published more than 400 original articles, supervised more than 32 Doctoral Theses (5 with Extraordinary Award and 3 with international mention), and given 200 international conferences in the main Endocrinology societies. He has received numerous awards and distinctions including the Andrea Prader Award for teaching and research in Pediatric Endocrinology in Europe (ESPE, 2019), Visionary Award (American Human Growth Foundation, 2020), International Hippocrates Award for Medical Research on Human Nutrition (2020). He has directed research projects of the European Community, FIS, and CM, being a collaborator in NIH and NATO projects. Dr. Argente researches the pathophysiology of human growth, puberty, and childhood obesity, having made discoveries about new genetic diseases in all three areas. He currently collaborates with Dr. A. García, METABOALL, on research related to obesity, insulin resistance, and anorexia in pediatric and adolescent patients. Professor Argente will participate in advising the consortium, as well as in the execution of the program at the scientific level, and will follow the evolution and progress of the consortium's activities given his extensive experience in the field.

The research team "Nuclear Receptor Signaling" led by Dr. Mercedes Ricote was established as a research group at the National Center for Cardiovascular Research (CNIC) in 2004. Recently, they have relocated their laboratory to the National Center for Biotechnology (CNB-CSIC), where Dr. Ricote is a researcher at the CSIC. The research team of Dr. Mercedes Ricote is composed of members with extensive experience in the study of macrophages and nuclear receptors in the context of chronic inflammatory diseases such as diabetes and atherosclerosis. The principal investigator has been working for over 20 years in the field of nuclear receptor signaling in metabolic and cardiovascular diseases and has obtained public funding (SAF2017-90604-REDT, RTI2018-095928-B-I00, PID2021-12255OB-B-I00), regional funding (B2017/BMD-3684, P2022/BMD-7227), private funding (Mutua Madrileña Foundation, La Marató TV3), and European funding (FP7-PEOPLE-2005-IRG, FP7-PEOPLE-2008-IEF, FP7-PEOPLE-2009-RG, EFSD/Lilly Research Fellowships, FP7-PEOPLE-2013-ITN) to conduct studies focused on elucidating the molecular mechanisms regulating macrophage activation and differentiation processes in homeostasis and in metabolic and cardiovascular diseases. Additionally, they have recently initiated a new line of research examining signal transmission between mothers and neonates and its impact on energy homeostasis control. To carry out these projects, the research group has established a wide range of state-of-the-art technologies such as omics (RNAseq, ChIPseq, and ATACseq), animal models, conditional knockout mice, and advanced non-invasive imaging techniques.

Additionally, Dr. Mercedes Ricote has supervised 7 doctoral theses and has overseen numerous master's projects and internships for vocational training students. Dr. Mercedes Ricote is invited to national and international congresses as a speaker and moderator at the level of "Keystone Symposium," "EMBO," FEBS..., indicating that she is a researcher of recognized prestige in the field of nuclear receptors. The research group has international collaborations with Drs. C. Glass (UCSD, La Jolla, USA), J. Cancelas (Cincinnati Children's Hospital, USA), D. Metzger (IGBMC, France), E. Treuter (Karolinksa Institute, Stockholm, Sweden); as well as national collaborations with groups belonging to MOIR2: Drs. G. Medina (URJC, Madrid) and M.P. Ramos (CEU, Madrid).

Financing for the last 5 years:

• [2023-2026]. COMMUNITY OF MADRID. Advancing in the knowledge of new markers, mechanisms, and tissue interactome in situations of insulin resistance. (P2022/BMD-7227). PI: Dr. M. Ricote.


• [2022-2025]. MINISTRY OF SCIENCE, INNOVATION AND UNIVERSITIES. Transcriptional and epigenetic control of the development of tissue-resident macrophages by nuclear receptors: role of the niche. (PID2021-12255OB-B-I00). PI: Dr. M. Ricote.


• [2019-2021]. MINISTRY OF SCIENCE, INNOVATION AND UNIVERSITIES. Role of the RXR nuclear receptor in the origin, differentiation, and functions of tissue macrophages. (RTI2018-095928-B-100). IP: Dr. M. Ricote.


• [2018-2020]. MINISTRY OF ECONOMY AND COMPETITIVENESS. Thematic network of nuclear receptors in cancer, metabolism, and inflammation. (SAF2017-90604-REDT). IP: Dr. M. Ricote. Coordinator: Dr. M. Ricote.


• [2018-2021]. COMMUNITY OF MADRID. Molecular Mechanisms and Intertissue Communication in Insulin Resistance. (B2017/BMD-3684). IP: Dr. M. Ricote. Coordinator: Dr. G. Medina.


• [2017-2019]. TV3 MARATÓ FOUNDATION. Systemic and tissue-specific control by nuclear receptors of obesity-induced insulin resistance. (ref. 201605-32). IP: Dr. M. Ricote. Coordinator: Dr. C. Caelles Franch.

Scientific Publications

2023

Paredes A, Justo-Méndez R, Jiménez-Blasco D, et al. γ-Linolenic acid in maternal milk drives cardiac metabolic maturation. Nature. 2023 ;618(7964):365-73. doi: 10.1038/s41586-023-06068-7

Menéndez-Gutiérrez MP, Porcuna J, Nayak R, et al. Retinoid X receptor promotes hematopoietic stem cell fitness and quiescence and preserves hematopoietic homeostasis. Blood .2023 ;141(6):592-608. doi: 10.1182/blood.2022016832

2022

Di Martino O, Ferris MA, Hadwiger G, et al. RXRA DT448/9PP generates a dominant active variant capable of inducing maturation in acute myeloid leukemia cells. Haematol . 2022 ;107(2):417-26. doi: 10.3324/haematol.2021.278603

2021

Porcuna J, Mínguez-Martínez J, Ricote M. The PPARα and PPARγ Epigenetic Landscape in Cancer and Immune and Metabolic Disorders. IJMS . 2021 ;22(19):10573. doi: 10.3390/ijms221910573

Paredes A, Santos-Clemente R, Ricote M. Untangling the Cooperative Role of Nuclear Receptors in Cardiovascular Physiology and Disease. IJMS . 2021 ;22(15):7775. doi:10.3390/ijms22157775

Font-Díaz J, Jiménez-Panizo A, Caelles C, et al. Nuclear receptors: Lipid and hormone sensors with essential roles in the control of cancer development. Seminars in Cancer Biology. 2021; 73:58-75. doi: 10.1016/j.semcancer.2020.12.007

Blanco-Domínguez R, Sánchez-Díaz R, De La Fuente H, et al. A Novel Circulating Noncoding Small RNA for the Detection of Acute Myocarditis. N Engl J Med . 2021 ;384(21):2014-27. doi: 10.1056/NEJMoa2003608

Di Martino O, Niu H, Hadwiger G, et al. Endogenous and combination retinoids are active in myelomonocytic leukemias. Haematol .2021 ; doi: 10.3324/haematol.2020.264432

2020

Muro-Pastor MI, Cutillas-Farray Á, Pérez-Rodríguez L, et al. CfrA, a Novel Carbon Flow Regulator, Adapts Carbon Metabolism to Nitrogen Deficiency in Cyanobacteria. Plant Physiol . 2020 ;184(4):1792-810. doi: 10.1104/pp.20.00802

Casanova-Acebes M, Menéndez-Gutiérrez MP, Porcuna J,et al. RXRs control serous macrophage neonatal expansion and identity and contribute to ovarian cancer progression. Nat Commun . 2020 ;11(1):1655. doi: 10.1038/s41467-020-15371-0

Alonso-Herranz L, Sahún-Español Á, Paredes A, et al. Macrophages promote endothelial-to-mesenchymal transition via MT1-MMP/TGFβ1 after myocardial infarction. eLife . 2020 ;9:e57920. doi: 10.7554/eLife.57920

Porcuna J, Menéndez-Gutiérrez MP, Ricote M. Molecular control of tissue-resident macrophage identity by nuclear receptors. Current Opinion in Pharmacology . 2020 ;53:27-34. doi: 10.1016/j.coph.2020.04.001

Ting SM, Zhao X, Sun G, et al. Brain Cleanup as a Potential Target for Poststroke Recovery: The Role of RXR (Retinoic X Receptor) in Phagocytes. Stroke . 2020 ;51(3):958-66. doi: 10.1161/STROKEAHA.119.02731

2019

Alonso-Herranz L, Porcuna J, Ricote M. Isolation and Purification of Tissue Resident Macrophages for the Analysis of Nuclear Receptor Activity. En: Gage MC, Pineda-Torra I, editores. Lipid-Activated Nuclear Receptors . New York, NY: Springer New York; 2019 . p. 59-73. Disponible en: http://link.springer.com/10.1007/978-1-4939-9130-3_5

Binek A, Rojo D, Godzien J, et al. Flow Cytometry Has a Significant Impact on the Cellular Metabolome. J Proteome Res. Jan 4;18(1):169-181, 2019. Disponible en: https://pubs.acs.org/doi/epdf/10.1021/acs.jproteome.8b00472